| Literature DB >> 33954072 |
Ryan Qasawa1, Daniel Yoho1, Jenna Luker1, Jake Markovicz1, Aamir Siddiqui1.
Abstract
Purpose For many providers, hand infections among diabetic patients is a condition that necessitates focused inpatient care. These patients are believed to have decreased innate immunity to fight infection, a more virulent course, and difficulty with recovery. Diabetes is considered by some to represent an additional risk factor that can result in an unfavorable outcome if not managed in an aggressive manner. Our own experience suggests that many of these patients can be safely managed in the outpatient setting. The purpose of this project was to better define the clinical outcomes for this population. Methods Evidence-based criteria were utilized to direct inpatient versus outpatient treatment pathways. A database was developed to track hand infections treated by the specialty service. The primary outcome was the resolution of hand infection. Secondary outcomes included specific treatment responses as well as patient characteristic comparisons of the different treatment groups. Independent variables included (parenteral and enteral) antibiotic use and bedside interventions performed. Patients were followed to complete the resolution of infection. Results For all patients managed as outpatients, diabetic patients had statistically significantly decreased improvement rates at two weeks as compared to non-diabetic patients (62% vs 75%, p =0.024). This difference disappeared at two months. Among diabetic patients, those with the highest rate of recovery at two weeks (90%) received intravenous antibiotics, bedside procedures, and oral antibiotics. Patients who did not receive antibiotics or undergo bedside procedures had the lowest percent of improvement (37%). Across all treatment subgroups, bedside procedure was the most impactful intervention. Less than 10% of patients were converted from outpatient to inpatient care, both diabetic and non-diabetic. Conclusions We reviewed our experience managing diabetes mellitus hand infections treated in the outpatient setting. Appropriate and effective treatment is possible, and the results are equivalent to those of patients without diabetes mellitus.Entities:
Keywords: diabetes; hand; infection; surgery
Year: 2021 PMID: 33954072 PMCID: PMC8088812 DOI: 10.7759/cureus.14263
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Database cases meeting inclusion criteria
Outpatient treatment subgroups with percentage improvement at two weeks and two months after treatment
DM, diabetes mellitus; IV abx, intravenous antibiotics; po abx, oral antibiotics; pro, bedside procedure
* One patient with delayed diagnosis of osteomyelitis of the distal phalanx. Required six weeks of oral antibiotics beginning at two point five (2.5) months after initial presentation. Complete resolution at four months.
| Group | Treatment | Patients (n) | Resolution at 2 Weeks (%) | Resolution at 2 Months (%) | Unplanned Return to the Emergency Department (n) | Converted to Inpatient Care (n)* |
| A | +IV abx, +pro, +po abx | 29 | 26 (90) | 29 (100) | 2 | 0 |
| B | +IV abx, -pro, +po abx | 13 | 7 (57) | 13 (100) | 1 | 2 |
| C | +IV abx, +pro, -po abx | 10 | 7 (70) | 10 (100) | 0 | 1 |
| D | +IV abx, -pro, -po abx | 19 | 6 (32) | 19 (100) | 0 | 4 |
| E | -IV ABX, -pro, +po abx | 28 | 20 (72) | 27 (95*) | 0 | 5 |
| F | -IV ABX, -pro, -po abx | 9 | 3 (37) | 9 (100) | 0 | 1 |
| Total DM | 108 | 67 (62) | 107 (99*) | 3 | 10 | |
| Total Non-DM | 343 | 257 (75) | 343 (100) | 6 | 24 |
Comparison of hand infection patients
DM, diabetes mellitus; HgA1c, hemoglobin A1c; MRSA, methicillin-resistance Staphylococcus aureus; po abx, oral antibiotics; IV, intravenous
*Significant comorbidities, including hypertension, myocardial infarction or cerebrovascular accident, acquired immunodeficiency, transplant, and Raynaud’s disease
†Wound cultures were only measured for patients undergoing an incisional or excisional procedure or who had an open wound
‡Baseline for this is the number of cultures performed, not the number of patients in the group
§Includes patients with previous history or current documentation of intravenous drug abuse
‖Includes patients lost to follow-up
| Outpatient DM (n=108) | Outpatient non-DM (n=343) | Inpatient DM (n=64) | Inpatient non-DM (n=113) | |
| Patients, n | 108 | 343 | 64 | 113 |
| Age, years | 47 + 25 | 48 + 33 | 52 + 31 | 50 + 27 |
| Gender, male (%) | 72 (67) | 213 (62) | 39 (61) | 67 (59) |
| HgA1c, % | 8.7 | - | 9.2 | - |
| Other comorbidities, (%)* | 13 (12) | 34 (10) | 46 (72) | 85 (75) |
| Wound culture performed, (%)† | 49 (45) | 127 (37) | 61 (95) | 108 (96) |
| MRSA culture‡ | 27 | 25 | 37 | 24 |
| Polymicrobial culture‡ | 36 | 32 | 47 | 51 |
| Gram-negative or anaerobic culture‡ | 4 | 0 | 3 | 2 |
| Received IV abx, (%) | 71 (66) | 250 (73) | 64 (100) | 113 (100) |
| Received po abx | 57 | 52 | 100 | 96 |
| Imaging performed | 68 | 61 | 87 | 83 |
| Incisional or excisional procedure | 38 | 29 | 100 | 94 |
| Intravenous drug abuse§ | 6 | 14 | 8 | 20 |
| Worker compensation case | 0 | 1 | 0 | 0 |
| Converted to inpatient care (%) | 10 (9) | 24 (7) | ||
| Resolution at 2 months (%) | 107 (99) | 343 (100) | 64 (100) | 113 (100) |
| Incomplete data‖ | 21 | 30 | 24 | 28 |